Browse drugs

…penia, hemolytic anemia, fever and Raynaud’s phenomenon, higher SLEDAI-2k. Anti-Sm positivity was associated with anti-C1q and anti-RNP-7…

…nalysis included the aggregated placebo arms from phase 2 and 3 anifrolumab trials (MUSE, TULIP-1, TULIP-2) in moderate-to-severe SLE. Phys…

…onal biomarkers for monitoring SLE activity being components of SLEDAI-2K, they may be insufficient in distinguishing high disease activi…

…48.2 years), 72% reported being PASS-A. Lower disease activity (SLEDAI-2K OR 0.95, 95% CI 0.92–0.99), DORIS remission (OR 2.48, 95% CI 1.…

…aseline disease duration, time from baseline to remission, mean prednisone daily dose, IS and antimalarials from baseline to remission. Pa…

… (29.4%) patients. Glucocorticoids were received by 41 (80.4%), hydroxychloroquine - 38 (74.5%), immunosuppressants – 18 (35.3%) patients. Over th…

…ity, 51% were of European ethnicity and 49% had active disease (SLEDAI-2K >4). Multiple overlapping protein associations between univaria…

… (p: 0.01), longer SLE history (p: 0.014), and higher values of SLEDAI-2K at the event and 10 years before (p: 0.0023 and p: 0.0003, resp…

…r organ activity, no new disease activity, PGA less than 1, and prednisone less than 7.5mg/day. Organ damage was measured with the SLICC/A…

…llow-up, with a reduction in disease flares and sparing of both prednisone and cDMARDs. Moreover, this case series highlights that BEL mai…

… this small real-world cohort of RTX-refractory/intolerant SLE, OBZ yielded promising responses, including in lupus nephritis, with…

…s Erythematosus Disease Activity Index 2000 (SLEDAI-2K): flare (SLEDAI-2K >6) or remission (SLEDAI-2K ≤6). A matched group of healthy con…